NATCO Announces Launch of the First Generic Version of Revlimid, in the U.S. market
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene.
New Delhi: NATCO Pharma Limited, NATCO Pharma Limited, along with its marketing partner Arrow International Ltd (an affiliate of Teva Pharmaceutical Industries Ltd), are pleased to announce launch of the first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the U.S. market.
The above strengths of lenalidomide capsules are prescribed in adults for the treatment of (1) multiple myeloma in combination with the medicine dexamethasone (2) certain myelodysplastic syndromes and (3) mantle cell lymphoma following specific prior treatment.
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).
Read Also - Natco Pharma inks pact with MPP to sell Molnupiravir capsules
Natco Pharma Limited was incorporated in Hyderabad in the year 1981. With a modest beginning of operations as a single unit with 20 employees, Natco today has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.
Read Also - Zydus gets DCGI nod for Oxemia
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.